KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables: 2020-2021

Historic Receivables for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Dec 2021 value amounting to $9.1 million.

  • Recursion Pharmaceuticals' Receivables rose 23736.73% to $11.7 million in Q2 2022 from the same period last year, while for Jun 2022 it was $34.4 million, marking a year-over-year change of. This contributed to the annual value of $9.1 million for FY2021, which is 5726.92% up from last year.
  • According to the latest figures from FY2021, Recursion Pharmaceuticals' Receivables is $9.1 million, which was up 5,726.92% from $156,000 recorded in FY2020.
  • Recursion Pharmaceuticals' Receivables' 5-year high stood at $9.1 million during FY2021, with a 5-year trough of $156,000 in FY2020.
  • Over the past 2 years, Recursion Pharmaceuticals' median Receivables value was $4.6 million (recorded in 2020), while the average stood at $4.6 million.
  • Data for Recursion Pharmaceuticals' Receivables shows a peak YoY soared of 5,726.92% (in 2021) over the last 5 years.
  • Yearly analysis of 2 years shows Recursion Pharmaceuticals' Receivables stood at $156,000 in 2020, then skyrocketed by 5,726.92% to $9.1 million in 2021.